Skip to search formSkip to main contentSkip to account menu

GSK 256066

Known as: GSK-256066, GSK256066 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phosphodiesterase 4 inhibitors attenuate virus‐induced activation of eosinophils from asthmatics without affecting virus binding
Acute respiratory virus infections, such as influenza and RSV, are predominant causes of asthma exacerbations. Eosinophils act as… 
2017
2017
P-262 A PDE4 Inhibitor-antibody Conjugate for Treating Ulcerative Colitis
Background: Although current treatment strategies for ulcerative colitis have been fairly effective, many ulcerative colitis… 
2017
2017
Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study
2015
2015
Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK‐256066 as Inhibitors of PDEB1 of Trypanosoma brucei
Cyclic nucleotide phosphodiesterases (PDEs) have been identified as important enzyme targets for drug development in both humans… 
2010
2010
A Four-week Randomized Study Of The Safety And Tolerability Of The Inhaled PDE4 Inhibitor GSK256066 In COPD
2010
2010
Gateways to clinical trials.
Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen… 
2009
2009
In VivoCharacterisation of GSK256066, an Exceptionally High Affinity and Selective PDE4 Inhibitor Suitable for Topical Administration.
2009
2009
In Vitro Characterisation of GSK256066, an Exceptionally High Affinity and Selective Inhibitor of PDE4 Suitable for Topical Administration.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)